India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
Italian contract researcher CROS NT has landed in the U.S., snapping up medical device-focused CRO Stat-Tech.
Two weeks after agreeing to become part of CRO giant Quintiles, Novella Clinical is promoting from within to prepare for future growth.
MPI Research has partnered up with two imaging outfits to open a state-of-the-art center for drug developers, and the trio has broken ground on what it calls a first-of-its-kind facility.
Twenty-two years after founding the Albany contract developer, AMRI CEO Thomas D'Ambra will retire from his post on New Year's Eve, leaving the helm as the company works to get out from regulatory scrutiny and grow revenue.
Contract manufacturer Patheon is still reaping the benefits of its high-dollar buyout of Banner Pharmacaps, wrapping up the integration process and reporting a 30.4% leap in quarterly profits.
CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.
Contract manufacturer Capsugel has signed a deal to buy Oregon's Bend Research, planning to fold that company's oral drug delivery technology into its growing innovative dosing business.
The FDA is adding teeth to rules requiring some drugmakers to conduct pediatric trials of new therapies, and the toughened enforcement could create an opportunity for CROs.
Despite concerns about slashed R&D budgets, overexpansion and consolidation, the titans of the CRO business are still posting double-digit growth, clocking $13.6 billion in 2012, according to a report.
Swiss CRO Psi is amping up its presence in Italy, the latest expansion for a clinical trial outfit looking to meet demand around the globe.
As research universities around the world look to put their labs to lucrative use by launching CROs, Duke University has nailed down another development deal, teaming up with the International Stem Cell Corporation on a Parkinson's disease treatment.
After months of regulatory woes and declining demand, Lonza is planning to cut two-thirds of its staff at a Massachusetts biologics plant, part of the CMO's overall effort to restructure and adapt to a changing market for commercial manufacturing.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.
Speaking to local business leaders in Research Triangle Park, Quintiles CEO Tom Pike said the life sciences' industry's biggest obstacle is comfort, as long-running biases in medicine can stave off innovation.
Cresset, a British provider of drug-discovery services, has faith in the market for early-phase work, and the company has expanded its staff and headquarters to prepare for an uptick in demand.
Switzerland's Psi is reaching into India's clinical research market, opening up shop in the country and continuing its global expansion.
Kansas CRO Vince & Associates, fresh from its private equity buyout, has expanded its endoscopy capabilities, beefing up its technology to attract more early-phase studies of gastrointestinal therapies.
High employee turnover rates have long been a fact of life in the CRO world, but more and more companies are being proactive, amping up their bonus offerings to lure and retain talent, according to study.
The FDA is encouraging drugmakers to embrace new methods of monitoring for clinical trials, and Icon is betting its latest offering can streamline how sponsors deal with study sites and save money in the process.